Journal of Clinical Oncology, Vol 17, Issue 3
(March), 1999: 832
© 1999 American Society for Clinical Oncology
Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study
Paul M. Zeltzer,
James M. Boyett,
Jonathan L. Finlay,
A. Lel Albright,
Lucy B. Rorke,
Jerrold M. Milstein,
Jeffrey C. Allen,
Kenneth R. Stevens,
Philip Stanley,
Hao Li,
Jeffrey H. Wisoff,
J. Russell Geyer,
Patsy McGuire-Cullen,
James A. Stehbens,
Susan B. Shurin,
Roger J. Packer
From the University of California at Irvine Medical Center, Orange, Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, and Childrens Hospital, Los Angeles, CA; St. Jude Children's Research Hospital, Memphis, TN; Memorial Sloan-Kettering Cancer Center, Beth Israel Medical Center, and New York University Medical Center, New York, NY; Children's Hospital of Pittsburgh, Pittsburgh, and Children's Hospital of Philadelphia, Philadelphia, PA; Children's Hospital and Medical Center, Seattle, WA; Doernbecher Children's Hospital, Portland, OR; Childrens Hospital of Denver, Denver, CO; Department of Pediatrics, University of Iowa, Iowa City, IA; Cleveland Rainbow Babies Hospital, Cleveland, OH; and Children's National Medical Center, Washington, DC.
Address reprint requests to Paul M. Zeltzer, MD, Children's Cancer Group, PO Box 60012, Arcadia, CA 91066-6012.
PURPOSE: From 1986 to 1992, "eight-drugs-in-one-day" (8-in-1) chemotherapy both before and after radiation therapy (XRT) (54 Gy tumor/36 Gy neuraxis) was compared with vincristine, lomustine (CCNU), and prednisone (VCP) after XRT in children with untreated, high-stage medulloblastoma (MB).
PATIENTS AND METHODS: Two hundred three eligible patients with an institutional diagnosis of MB were stratified by local invasion and metastatic stage (Chang T/M) and randomized to therapy. Median time at risk from study entry was 7.0 years.
RESULTS: Survival and progression-free survival (PFS) ± SE at 7 years were 55% ± 5% and 54% ± 5%, respectively. VCP was superior to 8-in-1 chemotherapy, with 5-year PFS rates of 63% ± 5% versus 45% ± 5%, respectively (P = .006). Upon central neuropathology review, 188 patients were confirmed as having MB and were the subjects for analyses of prognostic factors. Children aged 1.5 to younger than 3 years had inferior 5-year estimates of PFS, compared with children 3 years old or older (P = .0014; 32% ± 10% v 58% ± 4%, respectively). For MB patients 3 years of age or older, the prognostic effect of tumor spread (M0 v M1 v M2+) on PFS was powerful (P = .0006); 5-year PFS rates were 70% ± 5%, 57% ± 10%, and 40% ± 8%, respectively. PFS distributions at 5 years for patients with M0 tumors with less than 1.5 cm2 of residual tumor, versus  1.5 cm2 of residual tumor by scan, were significantly different (P = .023; 78% ± 6% v 54% ± 11%, respectively).
CONCLUSION: VCP plus XRT is a superior adjuvant combination compared with 8-in-1 chemotherapy plus XRT. For patients with M0 tumors, residual tumor bulk (not extent of resection) is a predictor for PFS. Patients with M0 tumors, 3 years with  1.5 cm2 residual tumor, had a 78% ± 6% 5-year PFS rate. Children younger than 3 years old who received a reduced XRT dosage had the lowest survival rate.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
T. J. Abouantoun and T. J. MacDonald
Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor
Mol. Cancer Ther.,
May 1, 2009;
8(5):
1137 - 1147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Pfister, M. Remke, A. Benner, F. Mendrzyk, G. Toedt, J. Felsberg, A. Wittmann, F. Devens, N. U. Gerber, S. Joos, et al.
Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the MYC and MYCN Loci
J. Clin. Oncol.,
April 1, 2009;
27(10):
1627 - 1636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lafay-Cousin and D. Strother
Current Treatment Approaches for Infants with Malignant Central Nervous System Tumors
Oncologist,
April 1, 2009;
14(4):
433 - 444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Gandola, M. Massimino, G. Cefalo, C. Solero, F. Spreafico, E. Pecori, D. Riva, P. Collini, E. Pignoli, F. Giangaspero, et al.
Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma
J. Clin. Oncol.,
February 1, 2009;
27(4):
566 - 571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rutkowski, N. U. Gerber, K. von Hoff, A. Gnekow, U. Bode, N. Graf, F. Berthold, G. Henze, J. E.A. Wolff, M. Warmuth-Metz, et al.
Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy
Neuro-oncol,
January 1, 2009;
11(2):
201 - 210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Pizer and S Clifford
Medulloblastoma: new insights into biology and treatment
Arch. Dis. Child. Ed. Pract.,
October 1, 2008;
93(5):
137 - 144.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. G. Gottardo and A. Gajjar
Chemotherapy for Malignant Brain Tumors of Childhood
J Child Neurol,
October 1, 2008;
23(10):
1149 - 1159.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. F. Pollack
Diagnostic and Therapeutic Stratification of Childhood Brain Tumors: Implications for Translational Research
J Child Neurol,
October 1, 2008;
23(10):
1179 - 1185.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Yasuda, H. Taguchi, Y. Sawamura, J. Ikeda, H. Aoyama, K. Fujieda, N. Ishii, M. Kashiwamura, Y. Iwasaki, and H. Shirato
Low-dose Craniospinal Irradiation and Ifosfamide, Cisplatin and Etoposide for Non-metastatic Embryonal Tumors in the Central Nervous System
Jpn. J. Clin. Oncol.,
July 1, 2008;
38(7):
486 - 492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N U Gerber, D Zehnder, T J Zuzak, A Poretti, E Boltshauser, and M A Grotzer
Outcome in children with brain tumours diagnosed in the first year of life: long-term complications and quality of life
Arch. Dis. Child.,
July 1, 2008;
93(7):
582 - 589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rossi, V. Caracciolo, G. Russo, K. Reiss, and A. Giordano
Medulloblastoma: From Molecular Pathology to Therapy
Clin. Cancer Res.,
February 15, 2008;
14(4):
971 - 976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. de Bont, J. M. Kros, M. M.C.J. Passier, R. E. Reddingius, P. A.E. S. Smitt, T. M. Luider, M. L. d. Boer, and R. Pieters
Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis
Neuro-oncol,
January 1, 2008;
10(5):
648 - 660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Lo, C. Ma, B. N. Bundy, S. L. Pomeroy, C. G. Eberhart, and J. K. Cowell
Gain of 1q Is a Potential Univariate Negative Prognostic Marker for Survival in Medulloblastoma
Clin. Cancer Res.,
December 1, 2007;
13(23):
7022 - 7028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Mabbott, M. Barnes, N. Laperriere, S. H. Landry, and E. Bouffet
Neurocognitive function in same-sex twins following focal radiation for medulloblastoma
Neuro-oncol,
October 1, 2007;
9(4):
460 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Rao, P. Bhoopathi, C. Chetty, M. Gujrati, and S. S. Lakka
MMP-9 Short Interfering RNA Induced Senescence Resulting in Inhibition of Medulloblastoma Growth via p16INK4a and Mitogen-Activated Protein Kinase Pathway
Cancer Res.,
May 15, 2007;
67(10):
4956 - 4964.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rutkowski, A. von Bueren, K. von Hoff, W. Hartmann, T. Shalaby, F. Deinlein, M. Warmuth-Metz, N. Soerensen, A. Emser, U. Bode, et al.
Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91
Clin. Cancer Res.,
May 1, 2007;
13(9):
2651 - 2657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Packer, A. Gajjar, G. Vezina, L. Rorke-Adams, P. C. Burger, P. L. Robertson, L. Bayer, D. LaFond, B. R. Donahue, M. H. Marymont, et al.
Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma
J. Clin. Oncol.,
September 1, 2006;
24(25):
4202 - 4208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Thompson, C. Fuller, T. L. Hogg, J. Dalton, D. Finkelstein, C. C. Lau, M. Chintagumpala, A. Adesina, D. M. Ashley, S. J. Kellie, et al.
Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations
J. Clin. Oncol.,
April 20, 2006;
24(12):
1924 - 1931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Mendrzyk, B. Radlwimmer, S. Joos, F. Kokocinski, A. Benner, D. E. Stange, K. Neben, H. Fiegler, N. P. Carter, G. Reifenberger, et al.
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma
J. Clin. Oncol.,
December 1, 2005;
23(34):
8853 - 8862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Geyer, R. Sposto, M. Jennings, J. M. Boyett, R. A. Axtell, D. Breiger, E. Broxson, B. Donahue, J. L. Finlay, J. W. Goldwein, et al.
Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children's Cancer Group
J. Clin. Oncol.,
October 20, 2005;
23(30):
7621 - 7631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kovanlikaya, A. Panigrahy, M. D. Krieger, I. Gonzalez-Gomez, N. Ghugre, J. G. McComb, F. H. Gilles, M. D. Nelson, and S. Bluml
Untreated Pediatric Primitive Neuroectodermal Tumor in Vivo: Quantitation of Taurine with MR Spectroscopy
Radiology,
September 1, 2005;
236(3):
1020 - 1025.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Oyharcabal-Bourden, C. Kalifa, J.C. Gentet, D. Frappaz, C. Edan, P. Chastagner, E. Sariban, A. Pagnier, A. Babin, F. Pichon, et al.
Standard-Risk Medulloblastoma Treated by Adjuvant Chemotherapy Followed by Reduced-Dose Craniospinal Radiation Therapy: A French Society of Pediatric Oncology Study
J. Clin. Oncol.,
July 20, 2005;
23(21):
4726 - 4734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Burzynski, R. A. Weaver, T. Janicki, B. Szymkowski, G. Jurida, M. Khan, and V. Dolgopolov
Long-term Survival of High-Risk Pediatric Patients With Primitive Neuroectodermal Tumors Treated With Antineoplastons A10 and AS2-1
Integr Cancer Ther,
June 1, 2005;
4(2):
168 - 177.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Rutkowski, U. Bode, F. Deinlein, H. Ottensmeier, M. Warmuth-Metz, N. Soerensen, N. Graf, A. Emser, T. Pietsch, J. E.A. Wolff, et al.
Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone
N. Engl. J. Med.,
March 10, 2005;
352(10):
978 - 986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. E. Reddick, J. O. Glass, S. L. Palmer, S. Wu, A. Gajjar, J. W. Langston, L. E. Kun, X. Xiong, and R. K. Mulhern
Atypical white matter volume development in children following craniospinal irradiation
Neuro-oncol,
January 1, 2005;
7(1):
12 - 19.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. N. Chi, S. L. Gardner, A. S. Levy, E. A. Knopp, D. C. Miller, J. H. Wisoff, H. L. Weiner, and J. L. Finlay
Feasibility and Response to Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma
J. Clin. Oncol.,
December 15, 2004;
22(24):
4881 - 4887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ray, M. Ho, J. Ma, R. K. Parkes, T. G. Mainprize, S. Ueda, J. McLaughlin, E. Bouffet, J. T. Rutka, and C. E. Hawkins
A Clinicobiological Model Predicting Survival in Medulloblastoma
Clin. Cancer Res.,
November 15, 2004;
10(22):
7613 - 7620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Lamont, C. S. McManamy, A. D. Pearson, S. C. Clifford, and D. W. Ellison
Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients
Clin. Cancer Res.,
August 15, 2004;
10(16):
5482 - 5493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Neben, A. Korshunov, A. Benner, G. Wrobel, M. Hahn, F. Kokocinski, A. Golanov, S. Joos, and P. Lichter
Microarray-Based Screening for Molecular Markers in Medulloblastoma Revealed STK15 as Independent Predictor for Survival
Cancer Res.,
May 1, 2004;
64(9):
3103 - 3111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Fernandez-Teijeiro, R. A. Betensky, L. M. Sturla, J. Y.H. Kim, P. Tamayo, and S. L. Pomeroy
Combining Gene Expression Profiles and Clinical Parameters for Risk Stratification in Medulloblastomas
J. Clin. Oncol.,
March 15, 2004;
22(6):
994 - 998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gajjar, R. Hernan, M. Kocak, C. Fuller, Y. Lee, P. J. McKinnon, D. Wallace, C. Lau, M. Chintagumpala, D. M. Ashley, et al.
Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for Medulloblastoma
J. Clin. Oncol.,
March 15, 2004;
22(6):
984 - 993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Fisher, P. C. Burger, and C. G. Eberhart
Biologic Risk Stratification of Medulloblastoma: The Real Time Is Now
J. Clin. Oncol.,
March 15, 2004;
22(6):
971 - 974.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Pingoud-Meier, D. Lang, A. J. Janss, L. B. Rorke, P. C. Phillips, T. Shalaby, and M. A. Grotzer
Loss of Caspase-8 Protein Expression Correlates with Unfavorable Survival Outcome in Childhood Medulloblastoma
Clin. Cancer Res.,
December 15, 2003;
9(17):
6401 - 6409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koeller and E. J. Rushing
From the Archives of the AFIP: Medulloblastoma: A Comprehensive Review with Radiologic-Pathologic Correlation
RadioGraphics,
November 1, 2003;
23(6):
1613 - 1637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Calabrese, A. Frank, K. Maclean, and R. Gilbertson
Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERK
J. Biol. Chem.,
July 4, 2003;
278(27):
24951 - 24959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Taylor, C. C. Bailey, K. Robinson, C. L. Weston, D. Ellison, J. Ironside, H. Lucraft, R. Gilbertson, D. M. Tait, D. A. Walker, et al.
Results of a Randomized Study of Preradiation Chemotherapy Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study
J. Clin. Oncol.,
April 15, 2003;
21(8):
1581 - 1591.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. MacDonald, B. R. Rood, M. R. Santi, G. Vezina, K. Bingaman, P. H. Cogen, and R. J. Packer
Advances in the Diagnosis, Molecular Genetics, and Treatment of Pediatric Embryonal CNS Tumors
Oncologist,
April 1, 2003;
8(2):
174 - 186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hernan, R. Fasheh, C. Calabrese, A. J. Frank, K. H. Maclean, D. Allard, R. Barraclough, and R. J. Gilbertson
ERBB2 Up-Regulates S100A4 and Several other Prometastatic Genes in Medulloblastoma
Cancer Res.,
January 1, 2003;
63(1):
140 - 148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Giordana, D. Duo, S. Gasverde, E. Trevisan, A. Boghi, I. Morra, L. Pradotto, A. Mauro, and A. Chio
MDM2 overexpression is associated with short survival in adults with medulloblastoma
Neuro-oncol,
April 1, 2002;
4(2):
115 - 122.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Grotzer, M. D. Hogarty, A. J. Janss, X. Liu, H. Zhao, A. Eggert, L. N. Sutton, L. B. Rorke, G. M. Brodeur, and P. C. Phillips
MYC Messenger RNA Expression Predicts Survival Outcome in Childhood Primitive Neuroectodermal Tumor/Medulloblastoma
Clin. Cancer Res.,
August 1, 2001;
7(8):
2425 - 2433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Kunschner, J. Kuttesch, K. Hess, and W.K. A. Yung
Survival and recurrence factors in adult medulloblastoma: The M.D. Anderson Cancer Center experience from 1978 to 1998
Neuro-oncol,
July 1, 2001;
3(3):
167 - 173.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. P. Meyers, S. L. Wildenhain, J.-K. Chang, E. C. Bourekas, P. F. Beattie, D. N. Korones, D. Davis, I. F. Pollack, and R. A. Zimmerman
Postoperative Evaluation for Disseminated Medulloblastoma Involving the Spine: Contrast-enhanced MR Findings, CSF Cytologic Analysis, Timing of Disease Occurrence, and Patient Outcomes
AJNR Am. J. Neuroradiol.,
October 1, 2000;
21(9):
1757 - 1765.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. A. Biegel, B. Fogelgren, J.-Y. Zhou, C. D. James, A. J. Janss, J. C. Allen, D. Zagzag, C. Raffel, and L. B. Rorke
Mutations of the INI1 Rhabdoid Tumor Suppressor Gene in Medulloblastomas and Primitive Neuroectodermal Tumors of the Central Nervous System
Clin. Cancer Res.,
July 1, 2000;
6(7):
2759 - 2763.
[Abstract]
[Full Text]
|
|
|
|
